Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $1.0K | $0 | $68.0K | $96.0K | $0 | $0 |
| Gross profit | $0 | −$1.0K | −$15.0K | −$68.0K | −$96.0K | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.1M | $7.9M | $15.0M | $38.6M | $64.2M | $53.2M | $93.1M |
| Operating income | −$3.3M | −$8.9M | −$23.0M | −$53.2M | −$81.4M | −$74.6M | −$113.5M |
| EBITDA | $1.0K | −$8.9M | −$23.0M | −$53.2M | −$81.3M | −$74.3M | −$113.5M |
| Net income | −$3.3M | −$9.6M | −$23.0M | −$51.5M | −$75.5M | −$69.6M | −$127.4M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.14 | -40.17 | -1.87 | -2.10 | -2.87 | -2.44 | -3193.30 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-0.79 | $-0.79–$-0.79 | 1 |
| 2027 | $22M | $-0.70 | $-0.70–$-0.70 | 1 |
| 2028 | $23M | $-0.72 | $-0.72–$-0.72 | 1 |
| 2029 | $0 | $-0.74 | $-0.74–$-0.74 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds AVTE.
No tracked institution reports a position in AVTE as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-04-29 | $2.4000 | 2025-04-28 |
| Execution date | Ratio |
|---|---|
| 2025-04-29 | 1-for-35reverse |
No one on the platform has traded AVTE yet.
| $145M |
| — |
| LABPLandos Biopharma, Inc. | $22.93 | +0.57% | $72M | — |
| MIROMiromatrix Medical Inc. | $3.39 | +0.59% | $93M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.